PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PROCEPT BioRobotics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$18.28+0.71 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
PROCEPT BioRobotics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Market Cap | $1.05B | $230.55M |
| Enterprise Value | $870.76M | $202.97M |
| PS Ratio | 3.10 | 3.11 |
| PB Ratio | 3.08 | 3.14 |
| P/TBV Ratio | 3.08 | 4.57 |
Enterprise value
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| EV / Sales | 2.58 | 2.92 |
Income (trailing twelve months)
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Revenue | $337.34M | $102.39M |
| Gross Profit | $216.65M | $60.36M |
| Operating Income | -$114.23M | -$4.31M |
| Net Income | -$109.76M | -$6.57M |
| EBITDA | -$107.18M | -$1.98M |
| EPS (Diluted) | -$1.94 | -$0.07 |
Margins
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Gross Margin | 64.2% | 55.1% |
| Operating Margin | -33.9% | -6.04% |
| Profit Margin | -32.5% | -10.5% |
| EBITDA Margin | -31.8% | -2.67% |
| FCF Margin | -25.2% | -0.30% |
Returns
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -30.2% | -19.2% |
| Return on Assets (ROA) | -22.1% | -13.3% |
| Return on Invested Capital (ROIC) | -60.5% | -4.11% |
| Return on Capital Employed (ROCE) | -27.5% | -9.07% |
Growth
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 22.7% | 8.85% |
| Revenue Growth (3Y CAGR) | 60.1% | 7.08% |
| Revenue Growth (5Y CAGR) | 109.0% | 11.8% |
Balance sheet
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $227.91M | $37.33M |
| Total Debt | $51.72M | $72.66M |
| Net Cash (Debt) | $176.20M | $3.92M |
| Net Cash Per Share | $3.08 | $0.28 |
| Equity (Book Value) | $340.07M | $57.36M |
| Book Value Per Share | $5.94 | $2.81 |
| Tangible Book Value | $340.07M | $10.71M |
| Working Capital | $356.09M | $54.64M |
Financial position
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Current Ratio | 6.55 | 2.50 |
| Quick Ratio | 5.23 | 1.54 |
| Debt / Equity | 0.15 | 0.38 |
| Interest Coverage | -32.89 | -1.81 |
Cash flow (trailing twelve months)
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Operating Cash Flow | -$74.34M | -$653.46K |
| Capital Expenditures | -$10.59M | -$3.69M |
| Free Cash Flow | -$84.93M | -$835.02K |
| FCF Per Share | -$1.48 | -$0.02 |
Efficiency
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Asset Turnover | 0.68 | 0.59 |
| Inventory Turnover | 1.68 | 2.21 |
| Revenue Per Employee | $379.89K | $322.57K |
| Profits Per Employee | -$123.60K | -$51.88K |
| Employee Count | 888 | 185 |
Dividends and yields
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Earnings Yield | -10.5% | -6.91% |
| FCF Yield | -8.11% | -0.56% |
Shares
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Shares Outstanding | 57,273,700 | 44,856,700 |
| Shares Change (YoY) | 4.24% | 3.35% |
| Shares Change (QoQ) | 0.62% | 0.27% |
| Float | 54,552,700 | 37,097,900 |
| Shares Held by Insiders | 4.75% | 10.6% |
| Shares Held by Institutions | 95.8% | 63.5% |
Scores
| Measure | PROCEPT BioRobotics | Industry median |
|---|---|---|
| Altman Z-Score | 3.27 | 1.95 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | -2.86 | -2.64 |
Calculated by StockData from PROCEPT BioRobotics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.